FreeTheAI

Hepion Pharmaceuticals Closes Gravitas Acquisition and Names New CEO

BearishHigh impact
HEPA$0.0610 −50.61%

Hepion Pharmaceuticals, Inc. (OTC:HEPA) completed its acquisition of Gravitas Life Sciences on Oct. 6, 2026. Along with the transaction, the company named Sireesh Appajosyula as Chief Executive Officer and Gary Stetz as Chief Financial Officer. Shares of Hepion plunged 50.61% to $0.061 following the updates.

The deal expands Hepion's drug candidate portfolio by adding GV104 and GV023. GV104 is being developed under a 505(b)(2) regulatory pathway with an active Investigational New Drug application. The U.S. Food and Drug Administration confirmed that no new dosing trials are required for GV104, reducing clinical uncertainty and allowing the company to concentrate on manufacturing requirements. Additionally, GV023 provides an oral infliximab candidate that is approaching initial clinical testing.

Looking ahead, key operational catalysts include progress on manufacturing for GV104 and regulatory approvals to initiate trials for GV023. The company is also aiming to validate a liver cancer ctRNA diagnostic test as a laboratory developed test in 2027 to potentially generate early revenue.

Key points

  • Hepion Pharmaceuticals completed its acquisition of Gravitas Life Sciences on Oct. 6, 2026.
  • Sireesh Appajosyula was named Chief Executive Officer and Gary Stetz was named Chief Financial Officer.
  • The FDA ruled that no new dosing studies are necessary for pipeline candidate GV104.
  • The company plans to launch a liver cancer ctRNA test as a laboratory developed test in 2027.
  • Shares of Hepion Pharmaceuticals fell 50.61% to $0.061.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Who is the new CEO of Hepion Pharmaceuticals?

Sireesh Appajosyula has been appointed as the new Chief Executive Officer of Hepion Pharmaceuticals, alongside Gary Stetz as Chief Financial Officer.

What did Hepion Pharmaceuticals acquire?

Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences on Oct. 6, 2026, acquiring the GV104 and GV023 drug programs.

Does GV104 require new FDA dosing studies?

No, the FDA confirmed that no new dosing studies are needed for GV104, shifting the primary focus to manufacturing.